Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCP | P55072 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ACACB | O00763 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | GABRP | O00591 | 1/20 | 0.38 |
| ▸ | GABRD | O14764 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.38 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.38 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.38 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.38 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16327701 | 0.85 | VCP (0.46) | VCPTDP1FFAR1KDM4EALDH1A1 | |
| SCHEMBL7636834 | 0.83 | NPSR1 (0.52) | VCPFFAR1KDM4EALDH1A1MAPT | |
| SCHEMBL11902648 | 0.81 | GABRP (0.49) | VCPTDP1FFAR1KDM4EALDH1A1 | |
| SCHEMBL12930159 | 0.80 | VCP (0.41) | VCPTDP1FFAR1KDM4EALDH1A1 | |
| SCHEMBL20089259 | 0.76 | VCP (0.55) | VCPTDP1FFAR1KDM4EALDH1A1 | |
| SCHEMBL12430908 | 0.74 | VCP (0.53) | VCPTDP1FFAR1KDM4EALDH1A1 | |
| SCHEMBL670335 | 0.74 | VCP (0.58) | VCPFFAR1ALDH1A1ACACBLMNA | |
| SCHEMBL18929859 | 0.73 | HTT (0.44) | VCPTDP1FFAR1ALDH1A1MAPT | |
| SCHEMBL14126185 | 0.72 | VCP (0.52) | VCPTDP1FFAR1KDM4EALDH1A1 | |
| SCHEMBL6781061 | 0.72 | VCP (0.52) | VCPFFAR1ALDH1A1ACACBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180334453-A1 | ISOINDOLINE DERIVATIVES | VIIV HEALTHCARE UK LIMITED (GB) | 2018-11-22 | — | — | US | disclosed |
| US-10112899-B2 | Isoindoline derivatives for use in the treatment of a viral infection | VIIV HEALTHCARE UK LIMITED (GB) | 2018-10-30 | — | — | US | disclosed |
| EP-3383863-A1 | ISOINDOLINE DERIVATIVES | ViiV Healthcare UK Limited (GB) | 2018-10-10 | — | — | EP | disclosed |
| US-20180244617-A1 | ISOINDOLINE DERIVATIVES FOR USE IN THE TREATMENT OF A VIRAL INFECTION | VIIV HEALTHCARE UK LIMITED (GB) | 2018-08-30 | — | — | US | disclosed |
| EP-3166925-B1 | ISOINDOLINE DERIVATIVES FOR USE IN THE TREATMENT OF A VIRAL INFECTION | VIIV HEALTHCARE UK LTD (GB) | 2018-03-14 | — | — | EP | disclosed |
| EP-3166925-B1 | ISOINDOLINE DERIVATIVES FOR USE IN THE TREATMENT OF A VIRAL INFECTION | VIIV HEALTHCARE UK LTD (GB) | 2018-03-14 | — | — | EP | disclosed |
| WO-2017093937-A1 | ISOINDOLINE DERIVATIVES | VIIV HEALTHCARE UK LIMITED (GB) | 2017-06-08 | — | — | WO | disclosed |
| WO-2017093937-A1 | ISOINDOLINE DERIVATIVES | VIIV HEALTHCARE UK LIMITED (GB) | 2017-06-08 | — | — | WO | disclosed |
| CN-106795141-A | Isoindoline derivatives for the treatment of viral infections | VIIV保健英国有限公司 | 2017-05-31 | — | — | CN | disclosed |
| EP-3166925-A1 | ISOINDOLINE DERIVATIVES FOR USE IN THE TREATMENT OF A VIRAL INFECTION | VIIV Healthcare UK Limited (GB) | 2017-05-17 | — | — | EP | disclosed |
| WO-2016005878-A1 | ISOINDOLINE DERIVATIVES FOR USE IN THE TREATMENT OF A VIRAL INFECTION | VIIV HEALTHCARE UK LIMITED (GB) | 2016-01-14 | — | — | WO | disclosed |
| WO-2016005878-A1 | ISOINDOLINE DERIVATIVES FOR USE IN THE TREATMENT OF A VIRAL INFECTION | VIIV HEALTHCARE UK LIMITED (GB) | 2016-01-14 | — | — | WO | disclosed |
| US-9018362-B2 | Oligonucleotide and use thereof | NATIONAL UNIVERSITY CORPORATION NAGOYA UNIVERSITY (JP) | 2015-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180244617-A1 | ISOINDOLINE DERIVATIVES FOR USE IN THE TREATMENT OF A VIRAL INFECTION | EIF2AK2, MAVS, OAT | VCP 1676/4885TDP1 1721/4885FFAR1 3745/4885 |
| US-20180334453-A1 | ISOINDOLINE DERIVATIVES | IRF3, EIF2AK2, MAVS | VCP 2301/4885TDP1 2060/4885FFAR1 3502/4885 |
| US-10112899-B2 | Isoindoline derivatives for use in the treatment of a viral infection | EIF2AK2, MAVS, OAT | VCP 1676/4885TDP1 1721/4885FFAR1 3745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.